Johnson & Johnson has entered a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharma company developing therapies and treatments for chronic hepatitis B virus (HBV) infection. The acquisition includes Novira’s portfolio of antivirals, including its lead candidate, NVR 3-778. The acquisition, subject to customary closing conditions, is expected to close during 4Q15. Financial terms were not disclosed. NVR 3-778 is a small molecule, dir...